Polypill: For Pollyanna

International Journal of Stroke

Volumn 3, Issue 2, 2008, Pages 92-97

  Spence, J David ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; CYANOCOBALAMIN; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; EZETIMIBE; FLUCONAZOLE; FOLIC ACID; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; MEVINOLIN; NADOLOL; PINDOLOL; PRAVASTATIN; PROPRANOLOL; SIMVASTATIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UBIDECARENONE;

ANGIONEUROTIC EDEMA; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLD LIMB; COUGHING; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; GOUT; GRAPEFRUIT; GYNECOMASTIA; HALLUCINATION; HEART FAILURE; HUMAN; HYPERTENSION; LIPID METABOLISM; LOW DRUG DOSE; MUSCLE BLOOD FLOW; MUSCLE CRAMP; MUSCLE METABOLISM; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; PAIN; PATIENT CARE; PILL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VIVID DREAM;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; DRUG THERAPY; FOLIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS; STROKE;

EID: 42449086463     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2008.00169.x     Document Type: Review

References (52)

1. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
2. Piepoli MF: Exercise rehabilitation Tn heart disease: the real "polypill" for primary and secondary prevention. Monaldi Arch Chest Dis 2005; 64: 88-93.
3. Sleight P, Pouleur H, Zannad F: Benefits, challenges, and registerability of the polypill. Eur Heart J 2006; 27: 1651-6.
4. Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP: The Aolymeal: a more natural, safer, and probably tastier (than the polypill) strategy to reduce cardiovascular disease by more than 75%. BMJ 2004; 329: 1447-50.
5. Amarenco P: Polypill strategy vs. prevention clinics for stroke prevention. Cerebrovasc Dis 2006; 21 (Suppl. 1): 35-40.
6. Franco OA, Steyerberg EW, de Laet C: The polypill: at what price would it become cost effective? J Epidemiol Commun Health 2006; 60: 213-7.
7. Fuster V, Sanz G: A polypill foT secondary prevention: time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med 2007; 4: 173.
8. Marentette MA, Gerth WC, Billings DK, Zarnke KB: Antihypertensive persistence and drug class. Can J Cardiol 2002; 18: 649-56.
9. Spence JD: How to Prevent Your Stroke. Nashville: Vanderbilt University Press, 2006.
10. Ismail R, Teh LK: The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther 2006; 31: 99-109.
11. Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
12. Egger T, Dormann H, Ahne G et al. Cytochrome p450 polymorphisms in geriatric patients: Impact on adverse drug reactions - a pilot study. Drugs Aging 2005; 22: 265-72.
13. Shand DG: Pharmacokinetics Af propranolol: a review. Postgrad Med J 1976; 52 (Suppl. 4): 22-5.
14. Shin J, Johnson JA: Pharmacogenetics of beta-blockers. Pharmacotherapy 2007; 27: 874-87.
15. Tweeddale MG, Ogilvie RI, Ruedy J: Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther 1977; 22: 519-27.
16. Dyckner T, Wester PO: Intracellular magnesium loss after diuretic administration. Drugs 1984; 28: 161-6.
17. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP: Diagnosis of sulfonamide hypersensitivity reactions by in-vitro 'rechallenge' with hydroxlamine metabolites. Ann Intern Med 1989; 110: 286-9.
18. Landmesser U, Drexler H: Effect of angiotensin II type 1 receptor antagonism on endothelial function: Role of bradykinin and nitric oxide. J Hypertens (Suppl.) 2006; 24: S39-43.
19. Blais C Jr., Rouleau JL, Brown NJ et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999; 43: 293-302.
20. Baer AN, Wortmann RL: Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007; 19: 67-73.
21. Vladutiu GD, Simmons Z, Isackson PJ et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34: 153-62.
22. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99: 1409-12.
23. Stein E, Stender S, Mata P et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004; 148: 447-55.
24. Kantola T, Kivisto KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397-402.
25. Lilja JJ, Neuvonen M, Neuvonen PJ: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004; 58: 56-60.
26. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
27. Lilja JJ, Kivisto KT, Neuvonen PJ: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66: 118-27.
28. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR: Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37: 1032-5.
29. Dreier JP, Endres M: Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 2004; 62: 670.
30. Spence JD: Drug interactions With grapefruit: whose responsibility is it to warn the public? [see comments]. Clin Pharmacol Ther 1997; 61: 395-400.
31. Graham IM, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-81.
32. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
33. Refsum H, Nurk E, Smith AD et al. The Hordaland homocysteine study: A community-based study of homocysteine, its determinants, and associations with disease. J Nutr 2006; 136: 1731S-40S.
34. Spence JD: Homocysteine-lAwering therapy: a role in stroke prevention? Lancet Neurol 2007; 6: 830-8.
35. Wang X, Qin X, Li H et al. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007; 369: 1876-82.
36. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998; 316: 894-8.
37. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD: Increased importance of Vitamin B12 for total homocysteine and carotid plaque in the era of folate fortification of the grain supply. CMAJ 2005; 172: 1569-73.
38. Quinlivan EP, McPartlin J, McNulty H et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002; 359: 227-8.
39. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340: 1449-54.
40. Andres E, Loukili NH, Noel E et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004; 171: 251-9.
41. Spence JD: Nutrition and stroke prevention. Stroke 2006; 37: 2430-5.
42. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP: Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002; 50: 1789-95.
43. Lonn E, Yusuf S, Arnold MJ et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
44. Spence JD: Homocysteine-lAwering therapy: a role in stroke prevention? Lancet Neurol 2007; 7: 830-8.
45. Khan NA, McAlister FA, Rabkin SW et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - therapy. Can J Cardiol 2006; 22: 583-93.
46. Baker EH, Duggal A, Dong Y et al. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension. Hypertension 2002; 40: 13-7.
47. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC: Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
48. Biglieri EG, Kater CE, Arteaga EE: Primary aldosteronism is composed of primary adrenal hyperplasia and adenoma. J Hypertens 1984; 2: S259-61.
49. Wallach L, NAarai I, Dawson KG: Stimulated renin: a screening test for hypertension. Ann Intern Med 1975; 82: 27-34.
50. Spence JD: Physiologic tailoring of therapy for resistant hypertension: 20 year' experience with stimulated renin profiling. Am J Hypertens 1999; 12: 1077-83.
51. Swift PA, MacGregor GA: Genetic variation in the epithelial sodium channel: A risk factor for hypertension in people of African origin. Adv Ren Replace Ther 2004; 11: 76-86.
52. Hackam DG, Spence JD: Combining multiple approaches for the secondary prevention of vascular events after stroke. A quantitative modeling study. Stroke 2007; 38: 1881-5.